CLINICAL TRIALS PROFILE FOR FLONASE
✉ Email this page to a colleague
All Clinical Trials for Flonase
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00119015 ↗ | The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis | Terminated | Merck Sharp & Dohme Corp. | Phase 4 | 2005-07-01 | Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug). |
| NCT00119015 ↗ | The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis | Terminated | University of Chicago | Phase 4 | 2005-07-01 | Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug). |
| NCT00275561 ↗ | Topical Steroid Treatment for Eosinophilic Esophagitis | Completed | Mayo Clinic | Phase 2 | 2005-11-01 | This was a randomized controlled trial of swallowed fluticasone vs. placebo for eosinophilic esophagitis. Eosinophilic esophagitis is an inflammatory condition in which the wall of the esophagus becomes filled with large numbers of eosinophils, a type of white blood cell. Patients who have this condition have difficulty in swallowing (dysphagia) solid food. Prior to treatment the patients had biopsies of their esophagus and took questionnaires regarding their symptoms. Treatment was given for 6 weeks, after which biopsies were taken from the esophagus to measure any changes in the tissue from before treatment. The primary endpoint was improvement in dysphagia as measured by the validated Mayo Dysphagia Questionaire. Secondary outcomes included partial symptom response, and histologic (tissue) response to treatment. |
| NCT00385463 ↗ | Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo | Withdrawn | GlaxoSmithKline | N/A | 2006-04-01 | The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study. The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations |
| NCT00385463 ↗ | Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo | Withdrawn | Creighton University | N/A | 2006-04-01 | The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. One of the drugs is for the treatment of asthma alone, one is for treatment of SAR alone, and one is for treatment of both SAR and asthma. In addition, you will also receive one asthma rescue drug (albuterol) that is to be used for any breakthrough asthma symptoms that you may experience throughout the study. The purpose of this study is to see how well your asthma and SAR are controlled when taking one of the medicine combinations |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Flonase
Condition Name
Clinical Trial Locations for Flonase
Trials by Country
Clinical Trial Progress for Flonase
Clinical Trial Phase
Clinical Trial Sponsors for Flonase
Sponsor Name
